Half-year report · HY
4885.TEDINET S100XFQT
Period2025-06-01 → 2025-11-30
Filed2026-01-14
StandardJapan GAAP
ConsolidatedNo
Data checks12 of 12 passed
Key figures · 50
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥3.7bn | 2025-06-01 → 2025-11-30 | Standalone | Net sales |
| Revenue | ¥6.7bn | 2024-06-01 → 2025-05-31 | Standalone | Net sales (5-year summary) |
| Revenue | ¥3.0bn | 2024-06-01 → 2024-11-30 | Standalone | Net sales |
| Operating income | ¥349m | 2025-06-01 → 2025-11-30 | Standalone | Operating income |
| Operating income | ¥154m | 2024-06-01 → 2024-11-30 | Standalone | Operating income |
| Ordinary income | ¥337m | 2025-06-01 → 2025-11-30 | Standalone | Ordinary income |
| Ordinary income | ¥430m | 2024-06-01 → 2025-05-31 | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥171m | 2024-06-01 → 2024-11-30 | Standalone | Ordinary income |
| Profit before tax | ¥336m | 2025-06-01 → 2025-11-30 | Standalone | Income before income taxes |
| Profit before tax | ¥171m | 2024-06-01 → 2024-11-30 | Standalone | Income before income taxes |
| Net income | ¥244m | 2025-06-01 → 2025-11-30 | Standalone | Profit loss |
| Net income | ¥241m | 2024-06-01 → 2025-05-31 | Standalone | Net income loss (5-year summary) |
| Net income | ¥121m | 2024-06-01 → 2024-11-30 | Standalone | Profit loss |
| Total assets | ¥6.5bn | at 2025-11-30 | Standalone | Assets |
| Total assets | ¥5.3bn | at 2025-05-31 | Standalone | Assets |
| Total assets | ¥5.5bn | at 2024-11-30 | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥3.8bn | at 2025-11-30 | Standalone | Liabilities |
| Total liabilities | ¥2.8bn | at 2025-05-31 | Standalone | Liabilities |
| Net assets / equity | ¥2.7bn | at 2025-11-30 | Standalone | Net assets |
| Net assets / equity | ¥2.5bn | at 2025-05-31 | Standalone | Net assets |
| Net assets / equity | ¥2.3bn | at 2024-11-30 | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥1.9bn | at 2025-11-30 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.1bn | at 2025-05-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥1.8bn | at 2025-11-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥1.0bn | at 2025-05-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥1.3bn | at 2024-11-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥1.1bn | at 2024-05-31v | Standalone | Cash and cash equivalents |
| Operating cash flow | ¥282m | 2025-06-01 → 2025-11-30 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | ¥216m | 2024-06-01 → 2025-05-31 | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥137m | 2024-06-01 → 2024-11-30 | Standalone | Net cash provided by used in operating activities |
| Investing cash flow | −¥141m | 2025-06-01 → 2025-11-30 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | −¥371m | 2024-06-01 → 2025-05-31 | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥188m | 2024-06-01 → 2024-11-30 | Standalone | Net cash provided by used in investment activities |
| Financing cash flow | ¥672m | 2025-06-01 → 2025-11-30 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | ¥123m | 2024-06-01 → 2025-05-31 | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥336m | 2024-06-01 → 2024-11-30 | Standalone | Net cash provided by used in financing activities |
| EPS (basic) | ¥60.85 | 2025-06-01 → 2025-11-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥60.42 | 2024-06-01 → 2025-05-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥30.29 | 2024-06-01 → 2024-11-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥59.98 | 2025-06-01 → 2025-11-30 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥59.49 | 2024-06-01 → 2025-05-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥29.82 | 2024-06-01 → 2024-11-30 | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥10 | 2025-06-01 → 2025-11-30 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥25 | 2024-06-01 → 2025-05-31 | Standalone | Dividend paid per share (5-year summary) |
| Equity ratio | 41.0% | at 2025-11-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 46.6% | at 2025-05-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 42.2% | at 2024-11-30 | Standalone | Equity to asset ratio (5-year summary) |
| Shares issued | 4,095,500 | at 2025-11-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,095,500 | at 2025-05-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,095,500 | at 2024-11-30 | Standalone | Total number of issued shares (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 24
| Segment | Item | Period | Value |
|---|---|---|---|
| Chemical Products Businessreportable segment | revenue | 2025-06-01 → 2025-11-30 | ¥1.3bn |
| Chemical Products Businessreportable segment | revenue external | 2025-06-01 → 2025-11-30 | ¥1.3bn |
| Chemical Products Businessreportable segment | segment profit | 2025-06-01 → 2025-11-30 | ¥58m |
| Healthy Food Businessreportable segment | revenue | 2025-06-01 → 2025-11-30 | ¥660m |
| Healthy Food Businessreportable segment | revenue external | 2025-06-01 → 2025-11-30 | ¥660m |
| Healthy Food Businessreportable segment | segment profit | 2025-06-01 → 2025-11-30 | ¥6m |
| Pharmaceutical Businessreportable segment | revenue | 2025-06-01 → 2025-11-30 | ¥1.8bn |
| Pharmaceutical Businessreportable segment | revenue external | 2025-06-01 → 2025-11-30 | ¥1.8bn |
| Pharmaceutical Businessreportable segment | segment profit | 2025-06-01 → 2025-11-30 | ¥285m |
| —segment total | revenue | 2025-06-01 → 2025-11-30 | ¥3.7bn |
| —segment total | revenue external | 2025-06-01 → 2025-11-30 | ¥3.7bn |
| —segment total | segment profit | 2025-06-01 → 2025-11-30 | ¥349m |
| Chemical Products Businessreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥1.1bn |
| Chemical Products Businessreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥1.1bn |
| Chemical Products Businessreportable segment | segment profit | 2024-06-01 → 2024-11-30 | −¥17m |
| Healthy Food Businessreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥523m |
| Healthy Food Businessreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥523m |
| Healthy Food Businessreportable segment | segment profit | 2024-06-01 → 2024-11-30 | ¥5m |
| Pharmaceutical Businessreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥1.4bn |
| Pharmaceutical Businessreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥1.4bn |
| Pharmaceutical Businessreportable segment | segment profit | 2024-06-01 → 2024-11-30 | ¥167m |
| —segment total | revenue | 2024-06-01 → 2024-11-30 | ¥3.0bn |
| —segment total | revenue external | 2024-06-01 → 2024-11-30 | ¥3.0bn |
| —segment total | segment profit | 2024-06-01 → 2024-11-30 | ¥154m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 490
| Item | Context | Value | Unit |
|---|---|---|---|
| Payments for lease and guarantee deposits inv cf | InterimDuration_NonConsolidatedMember | － | JPY |
| Proceeds from collection of lease and guarantee deposits inv cf | Prior1InterimDuration_NonConsolidatedMember | 86000 | JPY |
| Proceeds from collection of lease and guarantee deposits inv cf | InterimDuration_NonConsolidatedMember | 788000 | JPY |
| Purchase of insurance funds inv cf | Prior1InterimDuration_NonConsolidatedMember | -657000 | JPY |
| Purchase of insurance funds inv cf | InterimDuration_NonConsolidatedMember | -657000 | JPY |
| Other net inv cf | Prior1InterimDuration_NonConsolidatedMember | 655000 | JPY |
| Other net inv cf | InterimDuration_NonConsolidatedMember | -568000 | JPY |
| Net cash provided by used in investment activities | Prior1InterimDuration_NonConsolidatedMember | -188158000 | JPY |
| Net cash provided by used in investment activities | InterimDuration_NonConsolidatedMember | -141463000 | JPY |
| Proceeds from long term loans payable fin cf | Prior1InterimDuration_NonConsolidatedMember | 750000000 | JPY |
| Proceeds from long term loans payable fin cf | InterimDuration_NonConsolidatedMember | 1050000000 | JPY |
| Repayment of long term loans payable fin cf | Prior1InterimDuration_NonConsolidatedMember | -326704000 | JPY |
| Repayment of long term loans payable fin cf | InterimDuration_NonConsolidatedMember | -277750000 | JPY |
| Repayments of lease obligations fin cf | Prior1InterimDuration_NonConsolidatedMember | -978000 | JPY |
| Repayments of lease obligations fin cf | InterimDuration_NonConsolidatedMember | -559000 | JPY |
| Proceeds from exercise of stock option fin cf | Prior1InterimDuration_NonConsolidatedMember | 446000 | JPY |
| Proceeds from exercise of stock option fin cf | InterimDuration_NonConsolidatedMember | 174000 | JPY |
| Cash dividends paid fin cf | Prior1InterimDuration_NonConsolidatedMember | -87222000 | JPY |
| Cash dividends paid fin cf | InterimDuration_NonConsolidatedMember | -99901000 | JPY |
| Net cash provided by used in financing activities | Prior1InterimDuration_NonConsolidatedMember | 335541000 | JPY |
| Net cash provided by used in financing activities | InterimDuration_NonConsolidatedMember | 671964000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1InterimDuration_NonConsolidatedMember | -6174000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | InterimDuration_NonConsolidatedMember | 6206000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1InterimDuration_NonConsolidatedMember | 278382000 | JPY |
| Net increase decrease in cash and cash equivalents | InterimDuration_NonConsolidatedMember | 818215000 | JPY |
| Cash and cash equivalents | Prior2YearInstant_NonConsolidatedMember | 1050427000 | JPY |
| Cash and cash equivalents | Prior1YearInstant_NonConsolidatedMember | 1028068000 | JPY |
| Cash and cash equivalents | Prior1InterimInstant_NonConsolidatedMember | 1328809000 | JPY |
| Cash and cash equivalents | InterimInstant_NonConsolidatedMember | 1846284000 | JPY |
| Discounted trade notes receivable | Prior1YearInstant_NonConsolidatedMember | 9016000 | JPY |
| Discounted trade notes receivable | InterimInstant_NonConsolidatedMember | 543000 | JPY |
| Discounted electronically recorded monetary claims | Prior1YearInstant_NonConsolidatedMember | 739820000 | JPY |
| Discounted electronically recorded monetary claims | InterimInstant_NonConsolidatedMember | 303154000 | JPY |
| Electronically recorded monetary claim assignment | Prior1YearDuration_NonConsolidatedMember | 24308000 | JPY |
| Electronically recorded monetary claim assignment | InterimDuration_NonConsolidatedMember | 50402000 | JPY |
| Revenues from external customers | Prior1InterimDuration_NonConsolidatedMember_jpcrp040300-ssr_E36350-000PharmaceuticalBusinessReportableSegmentMember | 1352258000 | JPY |
| Revenues from external customers | Prior1InterimDuration_NonConsolidatedMember_jpcrp040300-ssr_E36350-000HealthyFoodBusinessReportableSegmentMember | 523451000 | JPY |
| Revenues from external customers | Prior1InterimDuration_NonConsolidatedMember_jpcrp040300-ssr_E36350-000ChemicalProductsBusinessReportableSegmentMember | 1089319000 | JPY |
| Revenues from external customers | Prior1InterimDuration_NonConsolidatedMember_ReportableSegmentsMember | 2965030000 | JPY |
| Revenues from external customers | Prior1InterimDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1InterimDuration_NonConsolidatedMember | 2965030000 | JPY |
| Transactions with other segments | Prior1InterimDuration_NonConsolidatedMember_jpcrp040300-ssr_E36350-000PharmaceuticalBusinessReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_NonConsolidatedMember_jpcrp040300-ssr_E36350-000HealthyFoodBusinessReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_NonConsolidatedMember_jpcrp040300-ssr_E36350-000ChemicalProductsBusinessReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_NonConsolidatedMember_ReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_NonConsolidatedMember | － | JPY |
| Net sales | Prior1InterimDuration_NonConsolidatedMember_jpcrp040300-ssr_E36350-000PharmaceuticalBusinessReportableSegmentMember | 1352258000 | JPY |
| Net sales | Prior1InterimDuration_NonConsolidatedMember_jpcrp040300-ssr_E36350-000HealthyFoodBusinessReportableSegmentMember | 523451000 | JPY |
| Net sales | Prior1InterimDuration_NonConsolidatedMember_jpcrp040300-ssr_E36350-000ChemicalProductsBusinessReportableSegmentMember | 1089319000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |